Abstract：Objective To study the clinical features and treatment outcome of children with mature B-cell non-Hodgkin's lymphoma (B-NHL). Methods A total of 28 previously untreated children with mature B-NHL were enrolled and given the chemotherapy regimen of CCCG-B-NHL-2010. Among them, 20 were given rituximab in addition to chemotherapy. The children were followed up for 31 months (ranged 4-70 months). A retrospective analysis was performed for the clinical features of these children. The Kaplan-Meier method was used for survival analysis. A univariate analysis was performed to investigate the prognostic factors. Results Among the 28 children, 17 (61%) had Burkitt lymphoma, 8 (29%) had diffuse large B-cell lymphoma (DLBCL), and 3 (11%) had unclassifiable B-cell lymphoma. As for the initial symptom, 13 (46%) had cervical mass, 10 (36%) had maxillofacial mass, 9 (32%) had hepatosplenomegaly, 5 (18%) had abdominal mass, and 5 (18%) had exophthalmos. Of all children, 14 had a lactate dehydrogenase (LDH) level of < 500 IU/L, 3 had a level of 500-1 000 IU/L, and 11 had a level of ≥ 1 000 IU/L. After two courses of chemotherapy, 21 children achieved complete remission and 7 achieved partial remission. At the end of follow-up, 24 achieved continuous complete remission and 4 experienced recurrence. The 2-year event-free survival rate was (85.7±6.6)%. The children with bone marrow infiltration suggested by bone marrow biopsy, serum LDH ≥500 IU/L, and bone marrow tumor cells > 25% had a low 2-year cumulative survival rate. Conclusions The CCCG-B-NHL 2010 chemotherapy regimen combined with rituximab has a satisfactory effect in the treatment of children with B-NHL. Bone marrow infiltration on bone marrow biopsy is associated with poor prognosis.
CHEN Zai-Sheng,ZHENG Yong-Zhi,CHEN Yi-Qiao et al. Clinical features and prognosis of children with mature B-cell non-Hodgkin's lymphoma: an analysis of 28 cases[J]. CJCP, 2018, 20(6): 470-474.
El-Mallawany NK, Cairo MS. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma[J]. Clin Adv Hematol Oncol, 2015, 13(2):113-123.
Cerci JJ, Györke T, Fanti S, et al. Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma[J]. J Nucl Med, 2014, 55(10):1591-1597.
[4]
Lee SH, Yoo KH, Sung KW, et al. Should children with non-Hodgkin lymphoma be treated with different protocols according to histopathologic subtype?[J]. Pediatr Blood Cancer, 2013, 60(11):1842-1847.
[5]
Masahito T, Tetsuya M, Akira K, et al. Improved treatment results of children with B-Cell non-Hodgkin lymphoma:A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study[J]. Pediatr Blood Cancer, 2014, 61(11):1215-1221.
[6]
Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence[J]. Br J Haematol, 2005, 131(1):39-49.
[7]
Worch J, Rohde M, Burkhardt B. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives[J]. Pediatr Hematol Oncol, 2013, 30(6):465-483.
Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children[J]. Br J Haematol, 2008, 142(3):329-347.
[14]
Cheson BD. Role of functional imaging in the management of lymphoma[J]. J Clin Oncol, 2011, 29(14):1844-1854.
[15]
Chen S,Wang S, He K, et al. PET/CT predicts bone marrow involvement in paediatric non-Hodgkin lymphoma and may preclude the need for bone marrow biopsy in selected patients[J]. Eur Radiol, 2018 Jan 30. doi:10.1007/s00330-018-5306-5.[Epub ahead of print].
[16]
Khan AB, Barrington SF, Mikhaeel NG, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement[J]. Blood, 2013, 122(1):61-67.
[17]
Adams HJ, Kwee TC, Fijnheer R, et al. Bone marrow 18 F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma[J]. Am J Hematol, 2014, 89(7):726-731.
[18]
Bhojwani D, McCarville MB, Choi JK, et al. The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma[J]. Br J Haematol, 2015, 168(6):845-853.
[19]
Sandlund JT. Non-Hodgkin Lymphoma in Children[J]. Curr Hematol Malig Rep, 2015, 10(3):237-243.
[20]
Szczepanowski M, Lange J, Kohler CW, et al. Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents[J]. Br J Haematol, 2017, 179(1):116-119.
[21]
Rohde M, Bonn BR, Zimmermann M, et al. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the NHL-BFM protocols[J]. Haematologica, 2017, 102(6):1091-1098.
